A Study to Evaluate the Efficacy and Safety of AD-221 and AD-221A

• Status: Recruiting
• Trial end date: 2022-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy and safety of AD-221 and AD-221A

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Addpharma Inc.
• Treatments: Atorvastatin; Ezetimibe

Criteria

Inclusion Criteria:

• Signed informed consent

• Subjects with primary hypercholesterolemia

Exclusion Criteria:

• Patient with secondary dyslipidemia

• Other exclusions applied